Formulations for transdermal or transmucosal application
First Claim
Patent Images
1. A formulation for transdermal or transmucosal administration of an active agent, the formulation comprising:
- at least one active agent, provided that when the active agent is estrogen, a progestin is not present in the formulation, and when the active agent is progestin, estrogen is not present in the formulation; and
a delivery vehicle comprising a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces;
wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
-
Citations
28 Claims
-
1. A formulation for transdermal or transmucosal administration of an active agent, the formulation comprising:
- at least one active agent, provided that when the active agent is estrogen, a progestin is not present in the formulation, and when the active agent is progestin, estrogen is not present in the formulation; and
a delivery vehicle comprising a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces;
wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 23, 28)
- at least one active agent, provided that when the active agent is estrogen, a progestin is not present in the formulation, and when the active agent is progestin, estrogen is not present in the formulation; and
-
21. A formulation for transdermal or transmucosal administration of an active agent, the formulation comprising:
- at least one active agent, provided that when the active agent is estrogen, a progestin is not present in the formulation, and when the active agent is progestin, estrogen is not present in the formulation; and
a delivery vehicle comprising a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol to provide permeation enhancement of the active agent through dermal or mucosal surfaces, wherein the polyalcohol is propylene glycol and is present in an amount between about 1% and 30% of the vehicle, the permeation enhancer is diethylene glycol monoethyl ether and is present in an amount of between about 0.2% and 25% of the vehicle, the alkanol is ethanol and is present in an amount of 5 to 75% by weight of the vehicle wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. - View Dependent Claims (22)
- at least one active agent, provided that when the active agent is estrogen, a progestin is not present in the formulation, and when the active agent is progestin, estrogen is not present in the formulation; and
-
24. A formulation for epithelial administration of an active agent, the formulation comprising:
- at least one active agent comprising an androgen; and
a delivery vehicle comprising a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through epidermal surfaces;
wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. - View Dependent Claims (25, 26, 27)
- at least one active agent comprising an androgen; and
Specification